Abstract: The present disclosure provides methods for using a chronic disease management (CDM) test to evaluate, diagnose, manage, facilitate, and inform clinical care of patients with chronic conditions, by providing a reliable and convenient diagnostic test for detecting medication nonadherence (NA) and drug-drug interactions (DDIs).

Abstract: A method for the detection and quantitation of pain medication in oral fluid specimens is provided. First, a Solid Phase Extraction (“SPE”) process is used to isolate cocaine and its metabolite, amphetamines and/or butalbital from human oral fluid samples. Alternatively, Liquid-Liquid Extraction (“LLE”) is used to isolate methadone and its metabolite, fentanyl and norfentanyl, buprenorphine and norbuprenorphine, propoxyphene and norpropoxyphene, carisoprodol, meprobamate, a series of benzodiazepines, tramadol and its metabolites, the analgesic opioids, and tetrahydrocannabinol (“THC”) and its carboxylated metabolite (“THC-C”). Finally, following isolation of these drugs and their metabolites, they are separated respectively using a high performance liquid chromatographic column and a novel combination chromatographic solvents and gradients. All analytes are detected and quantified using a tandem mass spectrometry (“MS/MS”) precursor to produce ion transitions.